CAJ | 학술논문

目的：评价阿德福韦联合贞芪扶正胶囊治疗慢性乙型肝炎(CHB)的疗效。方法按就诊的先后次序，将60例CHB患者在保肝治疗基础上，被随机分为治疗组和对照组，治疗组30例，对照组30例，治疗组联用贞芪扶正胶囊和阿德福韦，对照组为单用阿德福韦，两组疗程均为48周。观察用药前及用药后48周时的肝生化指标、HBVDNA载量、血清HBeAg阴转率及HbeAg血清转换率等变化。结果治疗后2组肝生化指标、HBV DNA载量均有不同程度的好转。治疗组ALT、AST的下降较对照组差异有统计学意义(P<0．05)。治疗后48周，治疗组HBVDNA阴转率为53.3％，明显高于对照组(33.3％)。血清HBeAg阴转率：治疗48周时，治疗组56.7％，对照组30.0％，两组差异均有统计学意义(P<0．05)。结论阿德福韦联合贞芪扶正胶囊治疗CHB，在恢复肝功能、降低HBVDNA载量及血清HBeAg阴转率方面均优于单用阿德福韦。
목적：평개아덕복위연합정기부정효낭치료만성을형간염(CHB)적료효。방법안취진적선후차서，장60례CHB환자재보간치료기출상，피수궤분위치료조화대조조，치료조30례，대조조30례，치료조련용정기부정효낭화아덕복위，대조조위단용아덕복위，량조료정균위48주。관찰용약전급용약후48주시적간생화지표、HBVDNA재량、혈청HBeAg음전솔급HbeAg혈청전환솔등변화。결과치료후2조간생화지표、HBV DNA재량균유불동정도적호전。치료조ALT、AST적하강교대조조차이유통계학의의(P<0．05)。치료후48주，치료조HBVDNA음전솔위53.3％，명현고우대조조(33.3％)。혈청HBeAg음전솔：치료48주시，치료조56.7％，대조조30.0％，량조차이균유통계학의의(P<0．05)。결론아덕복위연합정기부정효낭치료CHB，재회복간공능、강저HBVDNA재량급혈청HBeAg음전솔방면균우우단용아덕복위。
Objective To investigate the effect of adefovir single and it combined Zhenqifuzheng capsule in the treatment of chronic hepatitis B(CHB).Methods 60 patients of CHB on the basis of treating liver were divided into two groups randomly.There were 30 patienls in treatment group and30 patients in control group.The treatment group used Zhenqifuzheng capsule combined with adefovir,and the controlgroup used adefovir only,both treatment course were 48 weeks. The biochemical and HBVDNA load were determined by immunoassay after treatment with drugs for 48 weeks.Results The biochemical in liver was improved after treatment in two groups.The ALT and AST decreased in trial group more than the control group(P<0.05).The negative response rate of HBV DNA Was 53.3%.33.3%in trial group and control group.HBeAg seroeonvertion rate:after 48 weeks,the rate in treatment group(56.7%) was higher than that in conlrol group(30.0%). there was a statistical difference between the two group(P<0.05).Conclusion Adefovir combined with Zhenqifuzheng capsule for CHB is superior to adefovir alone in biochemical in liver,reducing the HBVDNA load and enhancing HBeAg seroconvertion rate.